Open Access

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long‑acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors

  • Authors:
    • Yuhong Wang
    • Wei Wang
    • Kaizhou Jin
    • Cheng Fang
    • Yuan Lin
    • Ling Xue
    • Shiting Feng
    • Zhiwei Zhou
    • Chenghao Shao
    • Minhu Chen
    • Xianjun Yu
    • Jie Chen
  • View Affiliations

  • Published online on: January 11, 2017     https://doi.org/10.3892/ol.2017.5591
  • Pages: 1165-1174
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastroenteropancreatic neuroendocrine neoplasm (GEP‑NEN) is known to overexpress somatostatin receptors (SSTRs), most commonly SSTR2 and SSTR5. The expression of SSTRs on tumor cells forms the basis for somatostatin analog treatment of patients with NEN. The present study detected the expression of SSTR2 and SSTR5 in GEP‑NEN and investigated the efficacy and safety of octreotide long‑acting release (LAR) in the treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP‑NET) in China. The present study reported that functionality of the pancreas, G1 and G2 grading, NET classification and Tumor‑Node‑Metastasis stages I and II were associated with higher SSTR2 positive expression. Similarly, SSTR5 was increased in pancreatic and well‑differentiated tumors. SSTR2 and SSTR5 positive expression predicted improved survival in GEP‑NEN patients. The median overall survival of patients treated with octreotide LAR was not reached. The median time to progression was 20.2 months, with the objective response rate being 5.6% and the stable disease rate being 79.6%. A total of 25.9% of the patients experienced adverse drug reactions. In conclusion, the present study demonstrated that SSTR2 and SSTR5 are heterogeneously expressed in GEP‑NEN. Both markers may serve as potential prognostic factors. Octreotide LAR is effective and safe in the treatment of Chinese patients with advanced GEP‑NET.

References

1 

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Fave G Delle, Kaltsas GA, Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9:61–72. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, Schindler M, Cole SL and Bussolati G: Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 440:461–475. 2002. View Article : Google Scholar : PubMed/NCBI

3 

Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y and Arnold R: Identification of somatostatin receptor subtypes 1, 2a, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 50:52–60. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Korner M, Eltschinger V, Waser B, Schonbrunn A and Reubi JC: Value of immunohistochemistry for somatostatin receptor subtype sst2a in cancer tissues: Lessons from the comparison of anti-sst2a antibodies with somatostatin receptor autoradiography. Am J Surg Pathol. 29:1642–1651. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Méndez G and Roca E: Buenos Aires and La Plata Argentina Argentum Working Group: Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 42:220–225. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, et al: Somatostatin receptor type 2a immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 20:1172–1182. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Hofland LJ and Lamberts SW: The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 24:28–47. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Oberg KE, Reubi JC, Kwekkeboom DJ and Krenning EP: Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 139:742–753, 753.e1. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Oberg K: Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 80:(Suppl 1). S57–S61. 2004. View Article : Google Scholar

10 

Appetecchia M and Baldelli R: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 29:192010. View Article : Google Scholar : PubMed/NCBI

11 

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the promid study group. J Clin Oncol. 27:4656–4663. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, et al: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 371:224–233. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Lim T, Lee J, Kim JJ, Lee JK, Lee KT, Kim YH, Kim KW, Kim S, Sohn TS, Choi DW, et al: Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in korea. Asia Pac J Clin Oncol. 7:293–299. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK and Modlin IM: Neuroendocrine tumor epidemiology: Contrasting norway and north america. Cancer. 113:2655–2664. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans DB: One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Wang YH, Lin Y, Xue L, Wang JH, Chen MH and Chen J: Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995–2012) in south china. BMC Endocr Disord. 12:302012. View Article : Google Scholar : PubMed/NCBI

17 

Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, et al: Phase ii study of sunitinib in japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs. 31:1265–1274. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 364:501–513. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Bosman F, Carneiro F, Hruban R and Theise N: Who classification of tumours of the digestive system. 4th. IARC Press; PA: 2010

20 

Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, et al: Tnm staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 449:395–401. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, et al: Tnm staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 451:757–762. 2007. View Article : Google Scholar : PubMed/NCBI

22 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Diakatou E, Kaltsas G, Tzivras M, Kanakis G, Papaliodi E and Kontogeorgos G: Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: An immunohistochemical study. Endocr Pathol. 22:24–30. 2011. View Article : Google Scholar : PubMed/NCBI

25 

van Adrichem RC, Kamp K, van Deurzen CH, Biermann K, Feelders RA, Franssen GJ, Kwekkeboom DJ, Hofland LJ and de Herder WW: Is there an additional value of somatostatin receptor subtype 2a immunohistochemistry over somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response? Neuroendocrinology. 103:560–566. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Sclafani F, Carnaghi C, Di Tommaso L, Rodari M, Destro A, Rimassa L, Giordano L, Chiti A, Roncalli M and Santoro A: Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori. 97:620–628. 2011.PubMed/NCBI

27 

Yerci O, Sehitoglu I, Ugras N, Cubukcu E, Yuce S, Bedir R and Cure E: Somatostatin receptor 2 and 5 expressions in gastroenteropancreatic neuroendocrine tumors in turkey. Asian Pac J Cancer Prev. 16:4377–4381. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, Kelley ST, Centeno BA, Coppola D, Malafa ME, et al: Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: Immunohistochemical approach with potential clinical utility. Cancer Control. 13:52–60. 2006.PubMed/NCBI

29 

Srirajaskanthan R, Watkins J, Marelli L, Khan K and Caplin ME: Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology. 89:308–314. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M and Koizumi W: Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2a to outcomes. Cancer. 119:4094–4102. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Kaemmerer D, Trager T, Hoffmeister M, Sipos B, Hommann M, Sänger J, Schulz S and Lupp A: Inverse expression of somatostatin and cxcr4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget. 6:27566–27579. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A and Fave G Delle: Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology. 89:223–230. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B and Pavel M: Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 98:137–143. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Broder MS, Beenhouwer D, Strosberg JR, Neary MP and Cherepanov D: Gastrointestinal neuroendocrine tumors treated with high dose octreotide-lar: A systematic literature review. World J Gastroenterol. 21:1945–1955. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE and Eriksson BK: High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 151:107–112. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, Severino R, Bellucci MC, Camera LM, Lombardi G, et al: Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 35:326–331. 2012.PubMed/NCBI

37 

Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A and Appetecchia M: Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: Current aspects and new perspectives. Front Endocrinol (Lausanne). 5:72014.PubMed/NCBI

38 

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI

39 

Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R and Yao JC: Fluorouracil, doxorubicin and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 22:4762–4771. 2004. View Article : Google Scholar : PubMed/NCBI

40 

Sun W, Lipsitz S, Catalano P, Mailliard JA and Haller DG: Eastern Cooperative Oncology Group: Phase ii/iii study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study e1281. J Clin Oncol. 23:4897–4904. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, Y., Wang, W., Jin, K., Fang, C., Lin, Y., Xue, L. ... Chen, J. (2017). Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long‑acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncology Letters, 13, 1165-1174. https://doi.org/10.3892/ol.2017.5591
MLA
Wang, Y., Wang, W., Jin, K., Fang, C., Lin, Y., Xue, L., Feng, S., Zhou, Z., Shao, C., Chen, M., Yu, X., Chen, J."Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long‑acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors". Oncology Letters 13.3 (2017): 1165-1174.
Chicago
Wang, Y., Wang, W., Jin, K., Fang, C., Lin, Y., Xue, L., Feng, S., Zhou, Z., Shao, C., Chen, M., Yu, X., Chen, J."Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long‑acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors". Oncology Letters 13, no. 3 (2017): 1165-1174. https://doi.org/10.3892/ol.2017.5591